New insider Moore Erin claimed ownership of 82,609 shares (SEC Form 3)
$SRRK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 03/21/2025 |
3. Issuer Name and Ticker or Trading Symbol
Scholar Rock Holding Corp [ SRRK ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 82,609(1) | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (Right to Buy) | (2) | 10/25/2028 | Common Stock | 16,764 | $23.86 | D | |
| Stock Option (Right to Buy) | (2) | 12/17/2029 | Common Stock | 6,463 | $11.48 | D | |
| Stock Option (Right to Buy) | (2) | 02/06/2030 | Common Stock | 49,288 | $13.52 | D | |
| Stock Option (Right to Buy) | (2) | 02/01/2031 | Common Stock | 35,000 | $58.93 | D | |
| Stock Option (Right to Buy) | (3) | 02/14/2032 | Common Stock | 25,000 | $18.08 | D | |
| Stock Option (Right to Buy) | (4) | 06/16/2032 | Common Stock | 17,425 | $4.86 | D | |
| Stock Option (Right to Buy) | (5) | 02/13/2033 | Common Stock | 31,250 | $10 | D | |
| Stock Option (Right to Buy) | (6) | 02/12/2034 | Common Stock | 40,000 | $15.75 | D | |
| Stock Option (Right to Buy) | (7) | 03/10/2035 | Common Stock | 25,715 | $35.15 | D | |
| Explanation of Responses: |
| 1. Consists of 15,380 shares of common stock and 67,229 restricted stock units ("RSUs"). Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. |
| 2. 100% of the shares underlying the option are fully vested. |
| 3. 6,250 shares remain unvested under this stock option. The first vesting event occurred on April 1, 2022 and the remainder will vest in fifteen quarterly installments thereafter; provided the reporting person continues to have a service relationship with the Issuer on such vesting date. |
| 4. 1,869 shares remain unvested under this stock option. The first vesting event occurred on September 16, 2022 and the remainder will vest in eleven quarterly installments thereafter; provided the reporting person continues to have a service relationship with the Issuer on such vesting date. |
| 5. 15,625 shares remain unvested under this stock option. The first vesting event occurred on April 1, 2023 and the remainder will vest in fifteen quarterly installments thereafter; provided the reporting person continues to have a service relationship with the Issuer on such vesting date. |
| 6. 30,000 shares remain unvested under this stock option. The first vesting event occurred on April 1, 2024 and the remainder will vest in fifteen quarterly installments thereafter; provided the reporting person continues to have a service relationship with the Issuer on such vesting date. |
| 7. Options to vest in sixteen quarterly installments over four years, with the first quarterly installment to vest on April 1, 2025 and each additional installment to vest quarterly thereafter; provided the individual continues to have a service relationship with the Issuer on such vesting date. |
| /s/ Junlin Ho, Attorney-in-Fact for Erin Moore | 03/21/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||